Lipitor Switch Decision Could Portend Pfizer’s Consumer Product Future
This article was originally published in The Tan Sheet
Executive Summary
As CEO Ian Read leaves open a door for the firm to unload the consumer business, industry consultant Steve Francesco says Pfizer’s decision to end its Lipitor switch program could move the business out the door.
You may also be interested in...
Pfizer Déjà Vu: Is It Time To Sell The Consumer Health Business?
As Pfizer re-examines a potential sale of its consumer business, analysts expect it would attract suitors with a likely price of $15bn to $17bn, but also say it might be better off continuing to compete in the sector that accounted for around $3.4bn of its 2016 revenues.
Pfizer Déjà Vu: Is It Time To Sell The Consumer Health Business?
As Pfizer re-examines a potential sale of its consumer business, analysts expect it would attract suitors for its unit, with $15bn to $17bn a likely price, but also say it might be better off continuing to compete in the sector that accounted for around $3.4bn of its 2016 revenues.
Pfizer Déjà Vu: Is It Time To Sell The Consumer Health Business?
As Pfizer re-examines a potential sale of its consumer business, analysts expect it would attract suitors for its unit, with $15bn to $17bn a likely price, but also say it might be better off continuing to compete in the sector that accounted for around $3.4bn of its 2016 revenues.